Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation ...

Core Viewpoint - TransMedics Group, Inc. (TMDX) has issued a statement refuting allegations made by short-seller Scorpion Capital, asserting that the claims are inaccurate and misleading, while reaffirming its commitment to operational integrity and compliance [1][8]. Company Performance - Following the announcement, TMDX shares dropped by 10.8%, closing at $57.2, and have seen a significant decline of 54% over the past three months, contrasting with the industry's growth of 1.2% and the S&P 500's increase of 3.4% during the same period [2]. - TMDX currently has a market capitalization of $1.92 billion and missed earnings estimates by 57.14% in the last reported quarter [4]. Allegations and Response - Scorpion Capital's report accused TransMedics of unethical practices, including kickbacks, billing fraud, and unreported device failures, suggesting these actions could lead to a customer exodus and financial decline, with a target stock price of $0 [5][7]. - In response, TransMedics categorically denied the allegations, stating they were baseless and aimed at market manipulation, while emphasizing its commitment to compliance and improving clinical outcomes in organ transplantation [8][9]. Future Outlook - The controversy surrounding the allegations could potentially benefit TMDX's share price in the long run if managed effectively, as the company's strong rebuttal may reassure investors and strengthen their confidence [3]. - TransMedics is preparing for significant business developments, including the launch of next-generation OCS Heart and OCS Lung programs in 2025 [9].

TMDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into TransMedics Group, Inc. and Encourages Investors to Contact the Firm ...

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX ...

The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into TransMedics Group, Inc. For Securities Fraud ...

TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation ...

RADNOR, Pa., Jan. 17, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of TransMedics Group, Inc. (NASDAQ: TMDX) ("TransMedics").On January 10, 2025, Scorpion Capital issued a short seller report on TransMedics. Specifically, the report alleged wrongdoing with respect to TransMedics' business practices, including fraudulent billing schemes, off-label misuse of its devic ...

Shares of organ transplant innovator TransMedics Group (TMDX -4.00%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence.TransMedics was the target of an activist short-seller late last week, and on Monday of this week, the company responded to the accusations at an industry health conference.While the stock initially bounced back a bit after the conference, it continued to fall through the week, as investors still appear to be skittish over the controversy.Scorpion at ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TransMedics Group, Inc. - TMDX ...

TransMedics Group, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm ...